1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | Licensing Program Analysts (LPA) Jey Cardenas conducted case management visit to the above facility; Upon arrival at the facility LPA conducted a risk assessment over the telephone with administrator, Sue Cooper; based on the assessment, the facility is clear of Covid-19 infection. LPA met with Miss Cooper, who assisted with the visit, the purpose of the visit was explained.
LPA observed deficiency during the complaint investigation visits which were conducted on 7/26/21 and 8/24/21; The following was discussed with the Administrator and staff; Per doctors’ orders R1 Risperidone should be given .125ML by mouth two times a day, may give another .125ML as needed for agitation at night. Per doctors’ orders R2 Risperidone should be given ½ML in the morning and 1 ML at bedtime. During interviews with staff#2 (S2) indicates that R1 is given a few drops of Risperidone; one time at night and R2 is given more Risperidone than R1, one time in the morning and one at night. Staff#3 (S3) indicates that R1 is given tiny amount one time a day after dinner and R2 is given one time after dinner. Administrator indicates that R1 is given .25ML Risperidone at night and R2 is given Risperidone one time at night. LPA found that Risperidone medication isn't being administered to resident according to doctors’ orders.
In addition, On 7/26/21 LPA also observed Medication Administration Record (MAR) for all six (6) residents were not being completed/ initialed by staff after medication was administered. S1 indicates that staff know when medication is administered to residents because they prep it in residents pill container for the day.
The following deficiency is cited under title 22 regulations, Exit interview conducted. Report to be provided via email with Appeal rights.
|